Centessa Pharmaceuticals (CNTA) Non Operating Income (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Non Operating Income of -$1.0 million for Q1 2026, down 199.9% year-over-year from $1.0 million in Q1 2025, and down 1095.15% quarter-over-quarter from $103000.0 in Q4 2025.
Centessa Pharmaceuticals (CNTA) Non Operating Income (2020 - 2026) Analysis & Trends
Centessa Pharmaceuticals (CNTA) has 7 years of Non Operating Income data on file, last reported at -$1.0 million in Q1 2026.
- Non Operating Income for Q1 2026 came in at -$1.0 million, down 199.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $860000.0 (down 1.83% YoY), and the FY2025 annual result was $2.9 million, up 272.55% from the prior year.
- Non Operating Income slipped to -$1.0 million in Q1 2026 per CNTA's latest filing, from $103000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $5.4 million in Q2 2022 and troughed at -$4.0 million in Q4 2024.
- A 5-year average of -$169823.5 and a median of -$878000.0 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income jumped 2905.76% in 2022, then plunged 1154.29% in 2023.
- A 5-year view of Non Operating Income shows it stood at -$70000.0 in 2022, then sank by 1154.29% to -$878000.0 in 2023, then sank by 351.94% to -$4.0 million in 2024, then jumped by 102.6% to $103000.0 in 2025, then slumped by 1095.15% to -$1.0 million in 2026.
- Business Quant data shows CNTA's Non Operating Income at -$1.0 million in Q1 2026, $103000.0 in Q4 2025, and -$1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Centessa Pharmaceuticals | 6.15 Bn | 6.15 Bn | - | -1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.03 Mn |
| Dec 31, 2025 | 103,000.00 |
| Sep 30, 2025 | -1.81 Mn |
| Jun 30, 2025 | 3.59 Mn |
| Mar 31, 2025 | 1.03 Mn |
| Dec 31, 2024 | -3.97 Mn |
| Sep 30, 2024 | 3.66 Mn |
| Jun 30, 2024 | 154,000.00 |
| Mar 31, 2024 | -1.54 Mn |
| Dec 31, 2023 | -878,000.00 |
| Sep 30, 2023 | -1.68 Mn |
| Jun 30, 2023 | -1.53 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Dec 31, 2022 | -70,000.00 |
| Sep 30, 2022 | -3.14 Mn |
| Jun 30, 2022 | 5.36 Mn |
| Mar 31, 2022 | 196,000.00 |
| Dec 31, 2021 | 235,000.00 |
| Sep 30, 2021 | -1.91 Mn |
| Jun 30, 2021 | -191,000.00 |